Background: Phaeochromocytoma (phaeo) and paraganglioma (PGL) are rare conditions, which are malignant in up to 30%. Optimal treatment is controversial, but in patients with metastatic iodine-131-meta-iodobenzylguanidine ( 123 I-MIBG) avid tumours, we offer
Results: Twenty-two patients (9 males) were identified, 12 with metastatic PGL and 10 with phaeo. Overall median follow-up time after first dose of 131 I-MIBG was 53 months. In total, 68 doses of 131 I-MIBG were administered; average dose was 9967 MBq (269.4 mCi). After the first dose, >50% of patients demonstrated disease stability or partial response; progressive disease was seen in 9%. A subset of patients underwent repeated treatment with the majority demonstrating partial response or stable disease. No life-threatening adverse events were reported, but three patients developed hypothyroidism and two developed ovarian failure after repeated dosing. Five-year survival after original diagnosis was 68% and median (+inter quartile range) survival from date of diagnosis was 17 years (7.6-26.4) with no difference in survival according to diagnosis (P < 0.1).
Conclusions:
131 I-MIBG is well tolerated and associates with disease stabilization or improvement in the majority of patients with metastatic phaeo/PGL. However, stronger conclusions on treatment effectiveness are limited by lack of a directly comparable 'control group' as well as an alternative 'gold standard' treatment.
Introduction
Phaeochromocytomas (phaeos) are tumours arising from the chromaffin cells of the adrenal medulla. Paragangliomas (PGLs) also arise from extra-adrenal tissue, mainly along the sympathetic (chromaffin derived) and parasympathetic (non-chromaffin origin) chains. Both tumours are extremely rare; their combined incidence is 8 per 100 000 patient years. 1 However, the incidence at post mortem is higher, suggesting that these tumours are under diagnosed. 2 The majority of phaeos and PGL are sporadic, although it is recognized that an increasingly significant proportion arises due to underlying germline mutations within RET (multiple endocrine neoplasia type 2), VHL (Von Hippel-Lindau), NF1 (neurofibromatosis type 1) and SDH (succinate dehydrogenase) genes. 3 It is likely that many other genetic causes of phaeo/PGL are to be identified and very recently, two further genetic mutations have been identified in familial phaeo (FP/TMEM127 and MAX genes). 4, 5 Although most cases of phaeo/PGL are benign, 17% of phaeos and up to 30% of PGL are malignant 6 ; risk of malignancy is higher in subjects with SDH mutations (especially succinate dehydrogenase B). 7 The only dependable indicator of malignant disease is the presence of metastatic disease in non-chromaffin tissues (e.g. liver, bone, lung and lymph nodes). 8 Therefore, it remains a challenge to recognize the malignant potential of tumours where metastases have not been identified at the time of diagnosis although recent evidence suggests that the size and location of primary tumours may be helpful. 6 There is no 'gold standard' algorithm for the optimal management of malignant disease although several guidelines exist. 9, 10 While surgical debulking of metastatic deposits is still advocated for palliation of symptoms, 11 if patients are asymptomatic with stable disease then close surveillance with no active treatment may be appropriate for a period of time. For other patients with symptomatic or progressive disease, not amenable or appropriate for surgery, then additional systemic therapy is required. Our local practice in such circumstances is to offer iodine-131-meta-iodobenzylguanidine ( 131 I-MIBG) therapy.
131
I-MIBG is structurally similar to noradrenaline and accumulates more rapidly in phaeo or PGL than normal tissue. 12 131 I-MIBG imaging remains helpful in localizing phaeo and, since 1983, has been used in the treatment of malignant phaeo/PGL in patients with 131 I-MIBG-avid disease. 13 The aim of this study was, therefore, to describe our experience of the use of 131 I-MIBG treatment in patients with metastatic phaeo/PGL in a single tertiary referral centre. We evaluated treatment by symptomatic, hormonal or tumour (radiological) response over a prolonged period of follow-up. In addition, we aimed to assess outcome and survival of our patient cohort as well as tolerability and safety of 131 I-MIBG therapy. 
Materials and Methods

Patients
Response to therapy (malignant disease cohort)
Objective tumour response was assessed according to standard World Health Organization (WHO) criteria as outlined in Table 1 .
Statistics
All data were analysed with IBM SPSS (version 18, NY) statistical analysis software. To evaluate response and its effect on outcome, we divided the groups into responders, including the partial and complete response patients and non-responders, including patients in the no-response and progression groups. This analysis was performed for symptomatic response, hormone response and tumour response. Kaplan-Meier statistics were performed for each group. Responders vs. non-responders were compared by use of the Wilcoxon and log rank tests. We defined statistical significance to be P < 0.05.
Results
Summary
General information
Complete clinical details were available for 22 patients with 123 I-MIBG-avid disease (9 males; median age 44.5 years) treated for metastatic phaeo (n = 10) and PGL (n = 12) between 1986 and 2012. Table 2 
Additional treatment
In the majority of subjects, 131 I-MIBG was administered after debulking surgery, but in three cases, 131 I-MIBG was the primary treatment due to inoperable disease at diagnosis.
Seven patients received chemotherapy in addition to 131 I-MIBG (subsequent to 131 I-MIBG in five cases), two of these patients also received external beam radiotherapy to bone metastases, and one further patient received adjuvant external beam radiotherapy only to rib metastases ( Table 2 ). The two subjects who received further 131 I-MIBG after chemotherapy were excluded from further analysis of 131 I-MIBG response (Table 4) . 
Genetic testing
Eight patients underwent genetic testing for mutations within genes known to predispose to PGL/phaeo (SDH-B/D; VHL and RET oncogene). Of these, four demonstrated no genetic abnormality, and four were found to have a mutation in the SDHB gene. No genetic testing information was available for one patient (patient 5), six others died before genetic screening was routinely offered and the other six were above the age (50 years) at which we routinely offered genetic screening at that time (upper age limit to longer applies to genetic screening of PGL patients).
Response 
Tolerability
Nausea and vomiting were the commonest side effects, occurring in 37 treatment episodes (54%). The true incidence of haematological side effects was hampered by missing full blood count data for the majority (44) episodes. Of the 24 episodes where information was available, transient 
Survival
On completion of the study (August 2012), nine patients (41%) were still alive. Of the 13 patients who had died, 11 had died as a direct consequence of metastatic disease. Five-year survival after original diagnosis was 68%. The median (+IQR) survival of all patients from date of diagnosis was 17 years (7.6-26.4) and was 11.1 years (0-22.7) after first dose of 131 I-MIBG (Figure 1a,b) . There was no significant difference in survival according to original diagnosis (P < 0.1; Figure 1c) . For the purposes of survival analysis, 131 I-MIBG symptomatic, hormonal and radiological (tumour) response was divided into three sub-groups: responders, stable disease and non-responders (disease progression). Using this sub-classification, a log rank test of significance demonstrated that patients who responded radiologically to the first dose of 131 I-MIBG demonstrated improved overall survival (P < 0.04; Figure 1d ). However, hormonal or symptomatic response to first dose of 131 I-MIBG did not influence overall survival (P < 0.3 in both cases).
Discussion
This retrospective review of the use of I-MIBG in this carefully selected group with the majority demonstrating stable disease or at least partial response at least 6 months after therapy.
We appreciate that the value of 131 I-MIBG is difficult to assess accurately within our cohort due to lack of a 'control' group of similar patients who did not undergo 131 I-MIBG therapy; without such a comparison, it is always difficult to know whether any impact on the natural history of this disease has been made. In particular, we acknowledge that, although the majority of patients demonstrated 'stable disease' after therapy, it is difficult to comment as to whether this was genuine or simply representative of a slow 'natural history' of the disease (although the majority did demonstrate biochemical or radiological progression prior to treatment). This is highlighted by a recent study exploring the natural history of malignant phaeo/ PGL in a cohort of 90 subjects from multiple centres in France. Fifty-seven of these patients had not previously undergone active treatment and yet demonstrated a mean progression free survival at 1 year of 46%. Therefore, surveillance of disease progression in the first instance is also a valid treatment approach in this circumstance. 14 This fact, as well as ethical concerns and the relative rarity of the condition, means that there has never been a randomized placebo-controlled study of the use of 131 I-MIBG in suitable patients with metastatic phaeo/PGL.
One major advantage of our long follow-up period is that we were able to demonstrate a median survival from time of diagnosis of 17 years and 11.1 years from time of first dose of 131 I-MIBG. The overall 5-year survival was 68%. This further demonstrates that the prognosis for metastatic phaeo/PGL, while highly variable, tends to be better than that for other metastatic malignancies with several patients demonstrating stable disease for prolonged periods (over 20 years in two cases). Although numbers were small in each cohort, there was no significant difference in median survival between phaeo or PGL patients; however, there was a trend towards improved survival in the phaeo group. Moreover, tumour (radiological) response to first dose of 131 I-MIBG does appear to impact favourably on survival. In a similar retrospective review of 33 patients with metastatic phaeo (n = 22) and PGL (n = 11) treated over a 10-year period, median survival after 131 I-MIBG administration was 56 months. 15 In common with our data, there was a trend towards increased survival in patients who demonstrated a measurable response to therapy.
131
I-MIBG was first used for the treatment of malignant phaeo in 1983, and since then, there have been several case series reported using various therapeutic protocols. [15] [16] [17] [18] [19] Our data compare favourably with other studies within this small patient group. In the largest and most comprehensive series to date (116 patients), investigators, using the WHO response criteria, demonstrated tumour response in 30%, stable disease in 57% and disease progression in 13%. 20 Subsequently, at an EANM Radionuclide Therapy Committee workshop on 131 I-MIBG therapy in 1999, the results of treatment of a cohort malignant phaeo (n = 77) and PGL (n = 34) patients were reported; the objective tumour response rates were 51 and 48%, respectively, in these patients with a significant (>50%) reduction in catecholamine excretion in 68 and 51%, respectively. The largest UK case series to date contained only 15 patients with malignant phaeo/PGL who underwent a median of three doses of 131 I-MIBG. Again, using the same WHO criteria employed in our study, they demonstrated a symptomatic response rate of 100%, complete or partial hormonal response in eight of nine patients and tumour reduction in 7 of 13 patients (54%). 17 Finally, a very recent meta-analysis (17 studies comprising 243 patients) exploring 131 I-MIBG use in this patient population resulted in stable tumour volume in 50% of subjects; again, this is comparable with our findings. 21 To date, there has only been one prospective phase 2 study of 131 I-MIBG therapy in metastatic phaeo/PGL. In this study of 50 patients, higher doses of 131 I-MIBG (18 000-43 000 MBq) were utilized, but response rates were comparable with our experience; 22% of subjects demonstrated complete or partial response to therapy and 35% demonstrated progressive disease 1 year after treatment. 22 The standard treatment protocol employed in our centre utilizes an 'intermediate' dose of 131 I-MIBG of 10 000 MBq (270 mCi) each time. This was well tolerated in our patient cohort; transient nausea and vomiting were seen in 37% of treatment episodes, whereas temporary myelosuppression was found in 38%. Although meaningful interpretation of our results is hampered by incomplete data collection, our rate of haematological side effects seems to be comparable with that described in a recent study by Sze et al. 23 In this retrospective case series, which included 14 phaeo/PGL subjects, haematological sequelae occurred in six patients (43%).
Predictably, ovarian failure developed in two women within our cohort after repeated dosing with a large cumulative dose of 131 I-MIBG. Hypothyroidism developed in three patients despite use of potassium iodate therapy. However, we have only recently included assessment of thyroid and ovarian function as part of our routine follow-up of patients who have received 131 I-MIBG therapy, and so our data may underestimate the rate of ovarian and/or thyroid failure.
There has been considerable debate over the optimal dosage regimens to confer benefit while not exposing the patient to an unacceptable risk of haematological toxicity. In the previous case series described by Safford et al., 15 there was a suggestion that patients who underwent high-dose initial therapy >18 500 MBq (>500 mCi) demonstrated an improvement in survival albeit with an increased risk of bone marrow suppression. In a subsequent small study of 12 patients administered high dose of 131 I-MIBG ranging from 14 300-31 820 MBq (386-866 mCi), a complete response was seen in three patients, two of who had skeletal and soft tissue metastases at the time of treatment. 24 Unsurprisingly, haematological complications were common in this cohort, with significant neutropenia in 79% of treatment episodes and requirement for stem cell infusion in one case. In addition, the rate of haematological sequelae in the prospective study of 131 I-MIBG therapy in which larger doses were utilized was relatively high with grade 3/4 neutropenia seen in 87%. 22 The data from our series, in common with others, support a multiple intermediate dose 131 I-MIBG regimen with better evidence of efficacy as well as safety and tolerability. 17, 19, 25 Strengths of our study include patient numbers, which, although small, represent a reasonably sized cohort of a rare disease. Another major strength is the duration of follow-up allowing robust information on survival and outcomes for a prolonged period after 131 I-MIBG therapy. The major limitation of this study is the retrospective collection of data, which, at times, was beyond 25 years resulting in incomplete information for some patients. Our policy of offering 131 I-MIBG therapy to all patients with 123 I-MIBG-avid metastatic disease has also meant that we cannot comment accurately on the 'natural history' of disease for many patients; this is particularly important given the recent data illustrating 49% progression free survival with no treatment at 1 year after diagnosis of malignant phaeo/PGL. 12 In addition, the lack of control group to allow comparison of outcomes with subjects with metastatic disease who did not undergo 131 I-MIBG has been acknowledged as a weakness; however, the rarity of this condition makes randomized, placebo-controlled or direct comparator studies extremely challenging.
In summary, these data support the concept that therapy with 131 I-MIBG has a definite role in the management of subjects with metastatic phaeo/ PGL. Our study demonstrates that 131 I-MIBG therapy in malignant disease provides sustained benefit particularly in terms of symptomatic relief and reducing tumour burden. This benefit can be maintained in selective individuals with repeated dosing. Importantly, 131 I-MIBG at modest doses (average 10 000 MBq or 270 mCi) is safe and well tolerated even when administered on multiple occasions.
